Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease, and its main pathological changes are chronic inflammation of the joint synovium and pannus formation [1–3]. RA not only is accompanied by progressive joint damage but also involves cardiovascular, lung, kidney, and multiple organ damage. Additionally, RA can lead to multiple rheumatic immune diseases, such as systemic lupus erythematosus, and declines in participation in social activities and quality of life. Furthermore, long-term medical treatment can increase the psychological burden of patients and even lead to mental illnesses such as depression [3, 4]. The pathogenesis of RA is unclear, and some studies have shown that RA pathogenesis is related to abnormal immune responses mediated by antigens (foreign or self), antigen-presenting cells, lymphocytes, and cytokines [1, 5, 6] In RA, inflammation is an important factor leading to disease progression, and inflammatory cytokines play an important role. Inflammatory cytokines include proinflammatory and anti-inflammatory cytokines. Proinflammatory cytokines include tumor necrosis factor (TNF-α), IL-6, IL-1, IL-1β, IL-17, IL-9, and M-CSF, which play key regulatory roles in cell proliferation, apoptosis, and innate and adaptive immunity. In addition, anti-inflammatory cytokines, including IL-4, IL-10, IL-13, and transforming growth factor-β (TGF-β), can balance the chronic activation of innate and adaptive immune cells [7, 8]. The treatment of RA is mainly based on targeting inflammatory cytokine receptors with biological agents and disease-modifying antirheumatic drugs (DMARDs). A TNF inhibitor (TNFi) that inhibits inflammation prior to RA is effective and popular in the clinic, but its long-term use can induce drug dependence and side effects. Research has shown that traditional Chinese medicine has great potential for the treatment of RA. In particular, emodin can effectively balance the levels of proinflammatory and anti-inflammatory cytokines to treat RA and thus prevent the adverse effects of targeting a single regulatory mechanism. Therefore, this article reviews the effect of emodin on the disease process of RA through the regulation of inflammatory cytokines.
2. Basic Biology of Emodin

The traditional Chinese medicine (TCM) RHEI RADIX ET RHIZOMA (Figure 1(a)) is called "Commander", was first recorded in the classic book “Shennong’s Herbal Classic” and was used clinically approximately 2,000 years ago in China. This representative TCM laxative can be used to treat coagulated cold by purgation, clearing heat-fire, eliminating blood stasis by catharsis, cooling the blood to resolve macula, clearing heat, and promoting diuresis [9, 10]. Modern research shows that Rt exerts good anti-inflammatory and antitumor effects and can regulate intestinal flora [11–13].

The main component of Rt is the anthraquinone, which can be further separated into free anthraquinone and conjugated anthraquinones, such as emodin, aloe-emodin, rhein, chrysophanol, and emodin methyl ether [14]. Emodin (chemical name: 1′3′8′-trihydroxy-6-methylanthraquinone; molecular weight: 270.24) (Figure 1(b)) is a class of biologically active natural products that has recently received much attention. Emodin has a variety of biological regulatory functions, such as immunosuppression and antitumor, antioxidant and anti-inflammatory activities (Figure 1(c)). Therefore, emodin has therapeutic potential in diseases of the cardiovascular system, respiratory system, metabolic system, nervous system, and other systems.

2.1. Pharmacokinetics of Emodin. The main metabolic pathway of emodin is glucuronidation metabolism, followed by sulfonation metabolism [15]. Emodin exists in the plasma, kidney, and lung as glucuronide or sulfate ester and in the liver as emodin in free form [16]. The absorption, excretion, tissue distribution, and metabolism of [14C] emodin have been studied in rats after a single oral administration (approximately 50 mg/kg). An analysis of the urine revealed excretion of 18% of the administered dose within 24 h and 22% of the administered dose within 72 h. The metabolites excreted in urine were mainly free anthraquinone, and the content of glucuronide or sulfate was only approximately 3%. At 24–120 h, the emodin detected in feces was mainly free, and the level equaled 48% or 68% of the administered dose. At 3–5 d, radioactivity was significantly reduced in most organs; however, high radioactivity remained in the kidneys until 5 d. At 72–120 h, radioactivity was greatly increased in mesenteric and adipose tissue [17]. An analysis of the half-life of emodin in rabbits revealed that its metabolic process in vivo involved a two-compartment open model. The AUC of emodin was 518 μg·min/mL, the clearance was 72.3 ml/min, and the elimination half-life was 227 min. The protein binding of emodin was investigated by the equilibrium dialysis method. Emodin was found to be highly bound (99.6%) to serum protein [18].

In vivo and in vitro experimental studies predicted that the target organs of emodin in which toxicity can occur are the kidney and liver [19], which may interfere with glutathione and fatty acid metabolism in human hepatocytes [20] and induce renal tubular pigmentation in male and female mice and an increase in the incidence of kidney disease in female mice. Moreover, emodin is reproductively toxic and inhibits human sperm function by reducing the sperm [Ca2+]i and inhibiting tyrosine phosphorylation in vitro [21].

2.2. Use of Emodin to Treat Human Diseases. Emodin has potential therapeutic effects on various diseases (Figure 2). Emodin can inhibit the proliferation and angiogenesis of tumor cells, reduce drug resistance and improve chemotherapy sensitivity in tumors and has a wide range of therapeutic effects on lung cancer, pancreatic cancer, breast cancer, and other tumors [22–25]. In metabolic disease, emodin improves dysglycemia and metabolic disorders in diabetes patients by inhibiting the activity of 11β-hydroxysteroid dehydrogenase type 1 inhibitor in adipose tissue [26], and in oral diseases, emodin reduces the nitric oxide (NO) levels in peripheral blood and gingival tissue and inhibits inflammatory responses and alveolar bone resorption [27]. In liver diseases, emodin can improve ethanol-mediated hepatic steatosis and treat alcoholic liver disease by downregulating the levels of alanine aminotransferase (ALT), triglyceride, and aspartate aminotransferase [28]. In microbial regulation, emodin can promote the expression of
related resistance genes in host cells, destroy microbial cell membranes and inhibit the replication of microbial DNA to effectively suppress the replication of pathogenic microorganisms and damage host cells [29–33]. Regarding oxidative stress damage, emodin exerts potential antioxidant effects, such as regulating the free radical and reactive oxygen species (ROS) levels and affecting oxidative stress-induced damage [34]. In cardiovascular diseases, emodin exerts potential therapeutic effects on diabetic retinopathy by inhibiting aldose reductase activity and improving retinal angiogenesis [35]. Emodin can also significantly inhibit the expression of TNF-α and activate the NF-κB signaling pathway in the local myocardial infarction area and can play a protective role in myocardial ischemia [36]. In respiratory diseases, emodin can effectively reduce pulmonary inflammatory cell infiltration, mucus secretion and serum IgE production, and regulate lung injury through IL-4-mediated macrophage polarization, STAT6 phosphorylation, and Nrf2 antioxidant signaling pathway activation [37, 38]. In neurological diseases, emodin directly protects nerve cells by regulating hormones, nerve growth factor (NGF), and related signaling pathways [39]. In immunomodulation, emodin can directly regulate the activity of immune cells or regulate related proinflammatory or anti-inflammatory cytokines secreted by immune cells and thereby regulate the inflammatory damage induced by immune disorders [40].

2.3. Regulation of Emodin in Immune Cells. The immunoregulatory function of emodin mainly affects the differentiation and maturation of T lymphocytes, dendritic cells (DCs), and regulatory T cells (Tregs) and the secretion of a variety of proinflammatory and anti-inflammatory cytokines to achieve immunomodulatory effects (Figure 3) [41].

T lymphocytes are also known as T cells and originate from bone marrow-derived lymphoid stem cells. T cells mainly include helper T (Th) cells (CD4+ cells), effector T (Te) cells, cytotoxic T (Tc) cells, virgin or natural T cells, and memory T (Tm) cells. CD4+ T cells are further classified as Th1, Th2, Th17, Treg, and Thh cells and play important roles in cellular immunity. Th1 cells can secrete the cytokines IFN-γ, IL-2, and TNF-α; as a result, Th1 cells, thus mediate the activation of macrophages through IFN-γ and the
proliferation of CD8+ T cells through IL-2, induce B cells to differentiate immunoglobulins, promote complement fixation and delayed-type hypersensitivity and aid in intracellular microbial clearance [42, 43]. Th2 cells can secrete IL-3, IL-4, IL-5, IL-10, and IL-13, and these cells can thereby mediate B-cell differentiation through IL-4, participate in allergic reactions and mediate macrophage deactivation through IL-4, IL-10 and IL-13 [44, 45]. Th17 cells can secrete the cytokines IL-17A, IL-17F, IL-22, and TNF-α and can mobilize and activate neutrophils through secreted IL-17 A/F, and these cells thereby induce autoimmune responses, tumor inflammatory responses, or transplant immune rejection [46]. Tregs can secrete the regulatory factor forhead box protein 3 (Foxp3) and the cytokines IL-4, IL-10, and TGF-β, which can inhibit the proliferation and activation of T cells through secreted IL-10 and TGF-β, and these cells, thus exert immunosuppressive effects and regulate autoimmune tolerance [47, 48]. Th1 cells can secrete the cytokines Bcl-6, IL-21, CXCR5, and ICOS, participate in information transmission during B-cell differentiation, aid the activation of B cells, promote the formation of germinal centers and the secretion of immunoglobulins, and maintain the long-term immune response [49, 50].

DCs originate from bone marrow pluripotent hematopoietic stem cells [51, 52], are the most powerful professional antigen-presenting cells (APCs) in the body and can efficiently take up, process, and present antigens [51]. DCs can induce the production of specific cytotoxic T lymphocytes (CTLs). The combination of DCs with T cells can result in high levels of IL-12 and IL-18 secretion and thereby activate T-cell proliferation, induce CTL generation, and dominate Th1 immune responses. DCs promote NK-cell killing via perforin P and FasL/Fas. DCs can also secrete specific chemokines to attract and recruit T cells and ultimately activate the inflammatory response of T cells [45, 53].

Tregs, which are a T-cell subset that controls autoimmune responses in the body, can be divided into naturally occurring natural regulatory T cells (nTregs), induced...
adaptive regulatory T cells (iTregs), CD8+ Tregs, and NK7 cells [54]. iTregs have not been shown to play an immunoregulatory role by secreting related cytokines. iTregs mainly include Tr1 and Th3 cells. Tr1 cells inhibit the proliferation of naïve and memory T cells by secreting IL-10 and TGF-β. Th3 cells can secrete a large amount of TGF-β, which has inhibitory effects on Th1 and Th2 cells. Th3 cells can secrete TGF-β, IL-4 and IL-10 after antigen-specific activation [55]. There are two subsets of CD8* Tregs, CD28+ and CD28−, and CD8*CD28− Tregs exert immunosuppressive effects [56]. Natural killer T cells (NKTs) are a unique group of αβ T cells that express the T-cell receptor (TCRαβ, b) and the NK-cell receptors NK1.1 or NK1c. In addition, NK cells can rapidly secrete a large amount of the Th2-type cytokines IL-4 and IL-10 and secrete IL-13 to regulate the function of CD8+ T cells, and these cells, thus, control the occurrence of various autoimmune diseases. In addition, NK cells can enhance immune killing effects through the rapid secretion of IFN-γ, TNF, and other Th1-type cytokines [57].

Emodin induces T-cell apoptosis in vitro through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction, and previous studies have revealed elevated levels of intracellular free Ca2+ and intracytoplasmic cytochrome C, the activation of cleaved caspase-3, caspase-9, and disruption of the mitochondrial membrane potential [40]. Emodin can inhibit the secretion of IFN-γ by T cells, reduce the numbers of CD3*CD4*IL4+, CD3*CD4* IFN-γ+, CD3*CD8*IL4+, and CD3*CD8* IFN-γ− T cells among peripheral blood mononuclear cells and splenic lymphocytes and exert anti-inflammatory effects [58]. In acute and severe inflammation, emodin regulates inflammation by regulating the ratios of TH1, TH2, TH17, and γδ T cells and regulating the secretion of interferon γ and IL-17 from γδ T cells [59]. In liver disease, emodin can effectively reduce the expression of proinflammatory cytokines and chemokines in the liver, including TNF-α, IFN-γ, IL-1β, IL-6, IL-12, inducible nitric oxide synthase (iNOS), integrin alpha M, chemokine ligand 2 (CCL2), macrophage inflammatory protein 2 (MIP-2), and chemokine (CXC motif) receptor 2 [60]. However, unlike nonglycosylated emodin, the emodin derivative 8-O-glucoside (E8G) can promote macrophage secretion of the proinflammatory cytokines TNF-α and IL-6 by upregulating the TLR-2/MAPK/NF-κB signaling pathway and exerting proinflammatory effects [61].

Emodin can inhibit the expression of CD80 and CD83 in DCs and the secretion of IL-12p70. Emodin-treated DCs exhibit reduced abilities to induce T lymphocyte proliferation and inhibit differentiation and maturation. In addition, emodin can inhibit the secretion of IL-12 by DCs, promote the secretion of IL-10, and inhibit the stimulatory effects of DCs on autologous T lymphocyte proliferation [62, 63]. In addition, physicin, a derivative of emodin, can effectively promote the expression of the DC surface molecule CD40, CD80, CD86, and MHC II, promote the secretion of cytokines by DCs, including IL-12p70, IL-1β, IL-6, and TNF-α, and induce the maturation of DCs. These effects further promote the differentiation of Th1 cells, do not affect the differentiation of Th2 cells, and effectively improve diseases induced by imbalances in Th1/Th2 cells [63].

In Tregs, emodin can significantly inhibit the expression of human leukocyte antigen (HLA-DR), glucocorticoid-induced tumor necrosis factor receptor (GIFTR), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and thereby induces Treg maturation and enhances the immunosuppressive function of CD4*CD25* Tregs [62]. Emodin can inhibit immune rejection by inducing the maturation of CD4*FoxP3+ and CD8*CD122+ Tregs and inhibiting the production of rejection antibodies [64].

These studies show that although emodin can act on multiple immune cells, it ultimately exerts its effects by affecting the secretion of inflammatory cytokines by these immune cells, and inflammatory cytokines are the main pathogenic causes of RA. Therefore, the treatment of inflammatory damage in RA can be achieved by regulating inflammatory cytokines.

3. Pathogenesis of RA

Genetic, environmental, and immune activation factors are associated with the pathogenesis of RA. (1) Genetic factors. Heritability of seropositive RA is observed in approximately 40–65% of cases, and seronegative RA is observed in approximately 20% of cases. Genome-wide association studies of single nucleotide polymorphisms have identified more than 100 genetic risk loci associated with RA, and most of these loci are associated with immune mechanisms [1, 5]. The HLA system (particularly HLA-DRB1), as the main influencing factor, promotes the effects of inflammatory and autologous polypeptides on the pathogenesis of RA and thereby exacerbates the inflammatory response. Other genetic loci may play a lesser role, but the effects induced by these loci have cumulative effects that ultimately affect costimulatory pathways, cytokine signaling, lymphocyte receptors, and innate immune activation [6]. (2) Environmental factors. The occurrence of RA is also related to environmental factors. The known risk factors include smoking, low socioeconomic status, and low educational level [65]. It has also been reported that RA is associated with periodontal disease, possibly because Porphyromonas gingivalis, a bacterium commonly detected in periodontitis, promotes the endogenous production of recombinant human arginine deiminase 4 (PADI4), which induces abnormal citrulline levels, promotes the conversion of arginine to citrulline, and ultimately reduces tissue tolerance to citrulline peptides [66, 67]. (3) Immune activation. The occurrence of RA may also be due to ACPAs forming immune complexes with citrulline-containing antigens. Subsequent binding to rheumatoid factor results in massive complement activation, which promotes the occurrence of an immune cascade. In addition, ACPAs can also be pathogenic by themselves. ACPAs may activate macrophages by binding to antigens to form complexes and then bind to toll-like receptors or Fc receptors to promote inflammatory responses and activate osteoclasts; ACPAs may also bind to citrulline vimentin and promote bone loss. Rheumatoid factor (RF) is more directly involved in the activation of macrophages and cytokines than ACPA [68].
4. Inflammatory Cytokines and the Pathology of RA

The pathological changes in RA joints that occur in RA patients include intra-articular and extra-articular changes. The basic pathological change in the joint occurs in synovitis, which manifests as synovial microvascular proliferation. The synovial lining cells proliferate from layers 1–2 to layers 8–10, and the synovial stroma contains a large number of T lymphocytes, plasma cells, and macrophages and shows infiltration of inflammatory cells such as T cells and neutrophils. Based on the above pathology, these cells and blood vessels invade cartilage or bone tissue and form an invasive pannus-cartilage-osseointegration area with obvious cartilage destruction and reduced levels of chondrocytes. The basic pathological changes outside the joints include vasculitis, which mainly manifests as necrotizing full-thickness arteritis of small arteries with mononuclear cell infiltration, intimal proliferation, thrombosis, small veins, and leukocytoclastic vasculitis [1]. The inflammatory cytokines TNF-α, IL-6, IL-4, IL-10, IL-13, IL-11, and TGF-β play a major dominant role in the pathological changes of synovitis. TNF-α is a cytokine with a wide range of effects that can modulate cell proliferation and apoptosis and innate and adaptive immune responses by regulating the NF-κB signaling pathway [69]. IL-6 mainly initiates inflammatory responses through the JAK/STAT signaling pathway, induces the phosphorylation of STAT3 in cells and participates in the activation and proliferation of fibroblasts, osteoclast differentiation, T-cell proliferation and survival, Th17-cell differentiation, B-cell survival, antibody production, and other processes [70, 71]. IL-4 can affect Th-cell differentiation, regulates the polarization and activity of macrophages, and inhibit the production of IL-1β and TNF-α by synovial macrophages, and as a result, this cytokine inhibits the development of inflammation [72, 73]. IL-10 activates the JAK1/STAT3 signaling pathway, reduces the release of proinflammatory mediators, and thereby suppresses the immune response [74–79]. IL-13 activates the NF-κB and STAT6 signaling pathways, induces monocyte differentiation, and inhibits inflammatory responses [80–85]. IL-11 acts on the JAK/STAT3 and NF-κB signaling pathways to reduce the production of IL-1 and TNF and thereby reduce the occurrence of inflammation [86]. TGF-β can inhibit the proliferation of T lymphocytes and thymocytes and thereby inhibit the immune cascade [87, 88]. The inflammatory cytokines IL-1 and IL-9 act on osteoblasts and osteoclasts during the pathological changes of bone erosion and bone destruction. IL-1 promotes the activation of leukocytes, endothelial cells, chondrocytes, and osteoclasts, and thereby exacerbates RA damage [89]. IL-9 can promote the formation and function of osteoclasts through the M-CSF/sRANKL signaling pathway, which in turn regulates the expression of matrix metalloproteinases (MMPs) and ultimately leads to bone damage in RA [90]. GM-CSF and IL-17 play major regulatory roles in the pathological changes in vasculitis. The synovium in RA patients expresses GM-CSF, and the level of GM-CSF in synovial fluid is increased. GM-CSF plays a key regulatory role in the differentiation, survival, and activation of macrophages and can promote the differentiation of Th17 cells, which ultimately affects the occurrence and development of RA [91–93]. IL-17 can stimulate synovial fibroblasts to produce vascular endothelial growth factor, promote angiogenesis, and increase the number of intra-articular blood vessels, and this cytokine thereby promotes the infiltration of inflammatory cells and their secreted cytokines and exacerbates the inflammatory response [94, 95]. Therefore, during the pathological changes that occur during RA, different inflammatory cytokines cause the different pathological mechanisms of RA.

5. Emodin Affects RA Procession by Regulating Inflammatory Cytokines

The immunomodulatory effects of emodin may be partly attributed to its anti-proliferative effects on lymphocytes and its regulation of the TH1/TH2 and TH17/Treg balance [96]. To inhibit inflammation, emodin reduces the levels of TNF-α and IL-6 in plasma and inhibits the production of PGE(2), the protein expression of COX-2 in synovial tissue [97] and the synergistic effect of the anti-inflammatory cytokines IL-4, IL-10, IL-13, IL-11 and TGF-β outside and inside cells. In the treatment of RA, emodin acts on synovial cells to inhibit inflammation by activating or inhibiting various signaling pathways, such as the JAK/STAT, NF-κB, and OPG/RANK-RANKL pathways (Table 1). In clinical practice, Rt clears heat toxins, regulates intestinal flora and improves the internal environment, and can also reduce the occurrence of RA by regulating intestinal bacteria. Inflammation is a double-edged sword and is essential for host defense [12, 13, 36–38]. In addition, the body’s inability to stop the inflammatory response leads to the uncontrolled destruction of cells and tissues and may lead to the development of chronic immune-mediated inflammatory diseases, allergies, or cancer.

Emodin can accelerate the resolution of inflammation by promoting granulocyte apoptosis [131], can significantly alleviate the symptoms of RA in a mouse model by regulating the activity of neutrophils in vivo, and can also reduce the occurrence and development of inflammation by regulating TNF-mediated inflammatory pathways [125, 126]. Emodin may improve symptoms of ulcerative colitis by regulating the flagellin-TLR5 signaling pathway [132]. Emodin induces apoptosis in fibroblasts in patients with ankylosing spondylitis by increasing the levels of active caspase-9, active caspase-3, and Bax and down-regulating the expression of Bcl-2 [133]. In the context of allergic reactions, emodin may exhibit antiallergic effects by increasing the stability of cell membranes and inhibiting the source of extracellular calcium [134]. In the context of autoimmune myocarditis in rats, emodin reduces TNF-α and IL-1β production to reduce inflammatory damage [135].
| Species          | Inflammatory cytokines | Target                  | Regulation results                                                                 | Refs.                  |
|------------------|------------------------|-------------------------|------------------------------------------------------------------------------------|------------------------|
|                  |                        | TNF-α, IL-6, IL-1β, IL-6, IL-33, MMP-10, and IL-8 decreased expression | [97–100]               |
|                  |                        | NF-κB                   |                                                                                    |                        |
|                  |                        | PI3K/AKT                | TNF-α, IL-6, PGE (2), and COX-2 decreased expression                                | [101, 102]             |
|                  |                        | FPGE2, C’ase            | PGE2, MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5 decreased expression                   | [98, 103–105]          |
|                  |                        | IL-17, G-CSF, CXC chemokine ligands 1 and 2 | Balance the ratio of TH1/TH2 cells and TH17/Tregs                                  | [69, 106, 107]         |
|                  |                        | IL-9, M-CSF/sRANKL      | Inhibiting the phosphorylation of IKK and RANKL expression                           | [108–110]              |
|                  |                        | JAK2/STAT5              | Enhances RANKL-dependent apoptosis of osteoclasts                                    | [92, 111–120]          |
|                  |                        | IL-4, MMP-13, metalloproteinase 3, and protein-like metalloproteinase 4 | Inhibiting the NF-κB/IRF5/STAT1 and IRF4/STAT6 signaling pathways, Inhibiting M1-to-M2 polarization of macrophages, and promoting Th1 cell polarization | [75, 121–123]         |
|                  |                        | IL-10, JAK1/STAT3       | Inhibiting the PI3K/AKT signaling pathways, inducing DC maturation, and promoting Th1 cell polarization | [124]                  |
|                  |                        | IL-13, STAT6            | IL-1β, TNF-α, IL-6, macrophage inflammatory protein 1α, macrophage inflammatory protein 1β, and macrophage inflammatory protein 3 decreased expression | [125–127]             |
|                  |                        | TGF-β, T cells, B cells, and thymocytes | Inhibiting the proliferation and differentiation of T cells, B cells, and thymocytes, limit the production of IL-2, IFN-γ, and TNF, and increase the secretion of GM-CSF | [42, 128–130]         |
5.1. Proinflammatory Cytokines. In RA, proinflammatory cytokines collectively promote the recruitment of leukocytes in the joints, induce chronic inflammation, stimulate osteoclast formation, induce the proliferation of synovial fibroblasts, lead to pannus formation, promote bone and cartilage degradation, and induce the release of other proinflammatory mediators, and these effects ultimately induce an inflammatory cascade that worsens the pathological changes that occur during RA.

5.1.1. TNF-α. TNF-α is produced by activated macrophages, monocytes, T cells, and other immune cells and plays a key role in cell proliferation, apoptosis, and innate and adaptive immunity. The various biological activities of TNF are mediated by the binding and activation of TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). TNFR1 is widely expressed, whereas TNFR2 expression is restricted to a few specific cell types, mainly including immune cells, endothelial cells, and other synovial cells [136–138]. As a proinflammatory factor, TNF-α can induce the proliferation of synovial cells in RA and reduce their apoptosis through the NF-κB signaling pathway. Emodin can inhibit the release of TNF from RBL-2H3 cells. In the collagen-induced arthritis (CIA) mouse model, emodin inhibits the levels of TNF-α and IL-6 in plasma [97]. Under hypoxic conditions, emodin reduces TNF-α, IL-6, IL-8, prostaglandin 2 (PGE2), MMP-1, MMP-13, and VEGF production in lipopolysaccharide (LPS)-induced synovial cells [98]. Emodin inhibits activation of the NF-κB signaling pathway by blocking the degradation of IκBα, directly acts on the NF-κB signaling pathway, and inhibits the degradation of the IκB subunit [99]. Studies have shown that external use of the traditional Chinese medicine compound rhubarb powder exerts a significant effect on relieving joint redness, swelling, heat, and pain in RA patients, and in an RA mouse model, this treatment can reduce the expression of IL-33, MMP-10, TNF-α, and other cytokines and increase the level of IL-10 and the ratio of OPG/RANKL, which results in controlling RA inflammation and preventing the exacerbation of disease [100].

5.1.2. IL-6. IL-6 is secreted by monocytes and macrophages following the binding of LPS to Toll-like receptors during infection, inflammation, or cancer [139]. IL-6 exerts biological effects through the IL-6 receptor (IL-6R), which consists of two subunits: a type 1 cytokine alpha receptor subunit (IL-6Rα or CD126) and a common signaling beta receptor subunit (gp130 or CD130) [140]. IL-6 is important for regulating B- and T-cell responses and coordinating the activities of the innate and adaptive immune systems [141]. In RA, IL-6 is highly expressed in serum and synovial tissue and mainly acts through the JAK/STAT signaling pathway to initiate inflammatory responses and induce the phosphorylation of STAT3. Emodin can increase the expression of TUG1 in WI-38 cells through the NF-κB and p38MAPK pathways and thereby reduces LPS-induced inflammatory injury [101]. Emodin also reduces the plasma levels of TNF-α and IL-6, PGE(2) production, and cyclooxygenase 2 (COX-2) protein expression in synovial tissue [102].

5.1.3. IL-1. IL-1 is produced by activated macrophages [142], is a key proinflammatory cytokine that affects immune cells, endothelial cells, and numerous target cells in the liver, and is a major causative factor in autoinflammation, autoimmune, and infection [143, 144]. Its ligands and receptor families are mainly associated with acute and chronic inflammation, and the cytoplasmic fragment of each IL-1 receptor family member contains a Toll-IL-1 receptor domain, which is also present in each Toll-like receptor. In vivo, these receptors respond to microbial products and viruses. One of the 11 members of the IL-1 family, IL-1β, has emerged as a therapeutic target for many systemic and local inflammatory diseases (autoinflammatory diseases), which can be treated by reducing IL-1β activity to cure acute and chronic inflammatory diseases, and the disease severity is influenced by the anti-inflammatory effects of IL-1 and its receptor [145]. IL-1β exerts proinflammatory effects, promotes vasodilation, activates innate immune cells (Neutrophils) [146, 147], and can act on T cells to induce the differentiation of Th17 cells [148]. High levels of IL-1 (IL-1α and IL-1β) in the synovial membrane and synovial fluid in RA can promote the expression of PGE2 and MMP in fibroblast-like synoviocytes (FLSs) [103, 104]. In a hypoxic environment, emodin can inhibit IL-1β and the LPS-induced increased expression of COX-2, VEGF, hypoxia-inducible factor 1α (HIF-1α), MMP-1, and MMP-13 [98, 105].

5.1.4. IL-17. IL-17 is a proinflammatory cytokine that is mainly secreted by Th17 and other T cells and plays an important role in adaptive immunity. In RA, IL-17 cooperates with TNF to increase the survival of synovial cells and promote their invasion and migration [149, 150]. IL-17 induces the production of G-CSF and CXC chemokine ligands 1 and 2 and thereby promotes the activation of T cells and neutrophils [151, 152]. In an RA model, the intrarticular injection of IL-17 antibodies effectively reduces synovitis symptoms and inhibits bone resorption [106]. The immunomodulatory effect of emodin may inhibit the proliferation of lymphocytes and balance the ratios of Th1 to Th2 cells and Th17 to Tregs. These findings, while providing evidence for the immunomodulatory mechanism of emodin, also have potential implications for promoting the use of emodin to treat RA [69]. In addition, emodin can inhibit viral myocarditis-associated damage by inhibiting the IL-23/IL-17 inflammatory axis, Th17-cell proliferation, and viral replication and thus exerts cardioprotective effects [107].

5.1.5. IL-9. Th9 cells are a newly identified subset of CD4+ T cells that secrete IL-9 [153]. rIL-9 stimulation can significantly enhance the secretion of nuclear factor and cytoplasmic 1 (NFATc1) by activated T cells; NFATc1 is a master transcriptional regulator of osteoclast differentiation in RA patients in whom the bone resorption capacity of osteoclasts and ultimately induces the differentiation of functional osteoclasts. In RA, IL-9 can lead to bone destruction by promoting osteoclastogenesis and regulating the expression of MMPs. Enhanced formation and function
of osteoclasts lead to the disruption of bone homeostasis, which ultimately induces bone destruction [108, 109]. IL-9 levels are elevated in the serum and synovial fluid in RA patients, and a strong correlation has been observed between synovial tissue inflammation and IL-9 levels. The stimulation of IL-9 significantly enhances M-CSF/sRANKL-mediated osteoclast formation and function. Studies have shown that emodin can inhibit the secretion of IL-9 by inhibiting the phosphorylation of IKK and the NF-κB signaling pathway, thereby inhibiting the proliferation of osteoclasts and reducing bone destruction in RA [110].

5.1.6. GM-CSF. GM-CSF is secreted by monocytes, lymphocytes, or fibroblasts and can regulate the differentiation, polarization, and activation of immune cells such as macrophages, DCs, and lymphocytes. GM-CSF is a secreted cytokine that belongs to the colony-stimulating factor family of hematopoietic growth factors and is also a proinflammatory cytokine [154–157]. In RA, the inflammatory changes induced by leukocyte activation can be suppressed using a GM-CSF antibody. The binding of GM-CSF to its receptor can affect downstream signaling molecules, such as JAK2/STAT, mitogen-activated protein kinase (MAPK), NF-κB, and phosphatidylinositol 3 kinase (PI3K), and in turn affect related signal transduction [91, 92, 111–118]. Studies have shown that anthraquinone compounds (emodin methyl ethers) can promote apoptosis in bone marrow cells and osteoclasts induced by GM-CSF and RANKL and promote the expression of osteopontin (OPG) in osteoblasts. In addition, anthraquinone compounds can effectively inhibit the expression of calcitonin receptor (CTR) and carbonic anhydrase/II (CAII) in osteoclasts induced by M-CSF and RANKL by inhibiting the JNK and NF-κB signaling pathways; therefore, anthraquinone compounds have the potential to inhibit bone resorption [119]. In addition, in a CIA mouse model, emodin inhibited macrophage-induced osteoclast differentiation and RANKL expression after M-CSF treatment [120].

5.2. Anti-Inflammatory Cytokines. Anti-inflammatory cytokines can neutralize proinflammatory cytokines and suppress both adaptive and innate immune responses. The common anti-inflammatory cytokines in RA are IL-4, IL-10, IL-13, and IL-11, which can balance the ratio between innate and adaptive immune cells [7, 8].

5.2.1. IL-4. IL-4 is secreted by mature Th2 cells, can promote the proliferation of Th2 cells, aid the activation of B cells, and play a role in humoral immunity. IL-4 inhibits the polarization and activity of macrophages induced by proinflammatory cytokines secreted by Th1 cells and enhances Th2 cell-mediated anti-inflammatory effects by regulating histone deacetylation. IL-4 also blocks or inhibits monocyte-derived cytokine secretion, including the secretion of IL-1, TNFα, IL-6, IL-8, and macrophage inflammatory protein (MIP)-1α. In RA, IL-4 can inhibit growth factor-induced synovial cell proliferation by interfering with the cell cycle and reducing cell survival and can exert antiangiogenic effects by inhibiting the production of vascular endothelial growth factor in FLSs [158–161]. IL-4, which is an endogenous regulator, inhibits mast cell development and mast cell progenitor survival, reduces the mast cell numbers in a mouse model of CIA and inhibits the production of IL-1β and TNF-α by synovial macrophages. In addition, IL-4 can inhibit the expression of MMP-13, tissue inhibitor of metalloproteinase 3, or disaggregation protein-like metalloproteinase 4 in chondrocytes. Therefore, IL-4 can inhibit inflammation and prevent bone destruction by regulating the expression of proinflammatory factors, inhibiting the proliferation of synovial cells, and affecting angiogenesis in FLSs [121, 122]. As observed in studies of emodin-regulated macrophages, emodin bidirectionally regulates LPS/IFN-γ and IL-4 response genes by inhibiting the NF-κB/IRF5/STAT1 and IRF4/STAT6 signaling pathways and thereby regulates the proliferation, differentiation, and generation of macrophages. As revealed by immunosuppression studies, emodin inhibits IL-2 production and promotes IL-4 secretion in mixed lymphocyte culture medium [123].

5.2.2. IL-10. IL-10 is an immunosuppressive cytokine secreted by T cells, B cells, monocytes, macrophages, neutrophils, and DCs. IL-10 is a potent inhibitor of the expression of Th1-type cytokines (IFN-γ, TNF-α, and IL-2), attenuates the surface expression of TNF receptors, and promotes the release of TNF receptors into the systemic circulation. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway is a key signaling pathway that mediates the effect of IL-10. IL-10 activates the JAK1/STAT3 signaling pathway after binding to its ligands, initiates specific DNA transcription in the nucleus, and exerts anti-inflammatory effects. In RA, IL-10 inhibits the expression of the proinflammatory factor TNF-α, prevents osteoclast activation, and reduces the degree of joint swelling, and as a result, this cytokine inhibits the progression of inflammation, relieves cartilage degradation, and exerts immunomodulatory effects [69]. In addition, in macrophages in the CIA mouse model, IL-10 deficiency leads to marked upregulation of IL-33 expression and aggravates the progression of CIA in the presence of STAT3 activation; IL-10 deficiency leads to marked upregulation of IL-33 expression and exacerbates the progression of CIA, and treatment with exogenous IL-10 inhibits IL-33 production in IL-10-knockout CIA mice. These results show that IL-33/ST2-mediated inflammation in macrophages is directly abrogated by IL-10 [124].

5.2.3. IL-13. IL-13 is secreted by mature Th2 cells; inhibits the proliferation of Th1 cells; downregulates TNF, IL-1, IL-8, and MIP-1 production by monocytes; upregulates the expression of major histocompatibility complex class II (MHC II) antigens; and activates STAT6 signaling pathway-dependent monocyte differentiation, and this cytokine thereby controls the inflammatory response [69]. In RA, IL-13 can inhibit the production of TNF-α by LPS-induced macrophages and reduce the expression levels of various
factors, such as the proinflammatory cytokines IL-1β, TNF-α, and IL-6 in synovial tissue; macrophage inflammatory protein 1α; macrophage inflammatory protein 1β; and macrophage inflammatory protein 3. IL-13 can also induce the transformation of inflammatory macrophages into anti-inflammatory macrophages, which secrete anti-inflammatory cytokines, such as IL-10 and TGF-β. In addition, IL-13 inhibits angiogenesis, synovial cells, and osteoblast apoptosis [125, 126]. In a mouse model of asthma, emodin can stimulate Th2 cells to secrete IL-4, IL-5, and IL-13, which could effectively delay the progression of airway inflammation [127]. Overall, in the RA model, emodin can regulate IL-13 by stimulating Th2 cells.

5.2.4. TGF-β. TGF-β can be produced by various cells, such as epithelial cells, immune cells, and fibroblasts [162, 163]. TGF-β can inhibit the proliferation and differentiation of T cells, B cells, and thymocytes, limit the production of IL-2, IFN-γ, and TNF; and increase the secretion of GM-CSF [133, 134, 164–166]. In a mouse model of asthma, TGF-β induces the expression of the transcription factor Foxp3 to convert peripheral CD4\(^+\)CD25\(^-\) naive T cells into CD4\(^+\)CD25\(^+\) regulatory T cells and thereby reduces allergic responses in the lungs [167]. In RA, TGF-β can enhance the regulatory function of B cells and thus promote the maturation and differentiation of Tregs and restrict the proliferation of T cells and their differentiation into Th1 and Th17 cells [168, 169]. TGF-β1 promotes the proliferation of human FLSs [128]. TGF-β can act on Th17 cells when combined with IL-6 or IL-21 and thereby inhibits the secretion of IL-17A/F and TNF-α by Th17 cells [129]. Emodin can promote the proliferation and differentiation of Tregs and Th3 secretion [42]. In addition, breast cancer studies have revealed that emodin inhibits TGF-β1 secretion by breast cancer cells and macrophages [130].

6. Conclusion and Perspective

Inflammatory cytokines play an important role throughout the whole process of RA occurrence and development, and RA can be treated by regulating inflammatory cytokines such as TNF-α, IL-6, IL-1β, IL-17, IL-4, IL-10, and IL-13. Targeting inflammation in RA is a treatment trend, and the simultaneous regulation of multiple inflammatory cytokines will be of great significance for the treatment of RA. Some cytokine-targeted biologics currently on the market are TNF-α receptor inhibitors (etanercept, adalimumab, infliximab, and certolizumab pegol), IL-6 receptor inhibitors (tocilizumab and sarilumab), and IL-1β receptor inhibitors (canakinumab), and some of these, such as IL-12 and IL-23 receptor inhibitors, are in the experimental stage. The
targeted biological mechanisms of these cytokine receptors exert substantial anti-inflammatory and bone protection effects in RA [7, 8], but caution is needed when biological agents are used in patients with low white blood cell counts, liver and kidney insufficiency, tuberculosis, and hepatitis B. In addition, the long-term use of biologics can lead to many serious adverse events, particularly infections and allergic reactions, which can increase the pressure and financial burden on patients and also cause mental and physical trauma to patients. Therefore, the identification of a reasonable, safe, and effective drug is important for the treatment of RA [170].

Emodin is a natural anthraquinone compound with various pharmacological effects, including anticancer, anti-inflammatory, antiviral, antibacterial, antiallergic, anti-osteoporosis, anti-diabetic, immunosuppressive, neuroprotective, and hepatoprotective effects. This compound has low immunogenicity and exerts strong anti-inflammatory effects; the main metabolic pathways are glucuronidation and sulfonation metabolism; emodin also exhibits high bioavailability and exerts a protective effect on patients with renal insufficiency. Regarding inflammatory cytokines, emodin further regulates various inflammatory diseases by regulating the secretion of cytokines and has no toxic side effects during the entire treatment process. Emodin, as an extract of a monomer used in traditional Chinese medicine, has many benefits and a low price and is easily accepted by the majority of patients (Figure 4).

Inflammatory cytokines are the most direct factors that lead to the occurrence and development of RA. The direct regulation of these cytokines is of great value to the treatment of RA. The simultaneous regulation of multiple inflammatory cytokines will be beneficial for the treatment of RA. However, recent studies have shown that the simultaneous use of two inflammatory cell-targeting biological agents in the treatment of RA increases the risk of infection in patients and has obvious side effects. As discussed in this review, emodin acts synergistically on proinflammatory and anti-inflammatory cytokines through multiple signaling pathways and has the potential to inhibit inflammatory damage in various diseases. Controlling inflammation will control the progression of RA, but the treatment of RA is not limited to directly inhibiting inflammation, and balancing the relationship between proinflammatory and anti-inflammatory cytokines will become a future direction of research on RA treatment. Emodin acts on a variety of proinflammatory cytokines and anti-inflammatory cytokines at the same time, and the effect is considerable. This review provides a reference for further combined drug treatment for RA in the future and is worthy of clinical application.

Data Availability
Not declared.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

References
[1] I. B. McInnes and G. Schett, "The pathogenesis of rheumatoid arthritis," New England Journal of Medicine, vol. 365, no. 23, pp. 2205–2219, 2011.
[2] D. M. Lee and M. E. Weinblatt, "Rheumatoid arthritis," Lancet, vol. 358, no. 9285, pp. 903–911, 2001.
[3] A. J. Silman, J. E. Pearson, and T. Pincus, "Epidemiology and genetics of rheumatoid arthritis," Arthritis Research, vol. 4, pp. S265–S272, 2002.
[4] I. B. McInnes, "Georg Schett, Pathogenetic insights from the treatment of rheumatoid arthritis," Lancet, vol. 389, pp. 2328–2337, 2017.
[5] A. I. Catrina, V. Joshua, L. Klareskog, and V. Malmström, "Mechanisms involved in triggering rheumatoid arthritis," Immunological Reviews, vol. 269, pp. 162–174, 2016.
[6] E. M. Tan and J. S. Smolen, "Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor," Journal of Experimental Medicine, vol. 213, pp. 1937–1950, 2016.
[7] Z. Chen, A. Bozec, A. Ramming, and G. Schett, "Anti-inflammation and Immune-regulatory cytokines in rheumatoid arthritis," Nature Reviews Rheumatology, vol. 15, no. 1, pp. 9–17, 2019.
[8] E. Y. Kim and K. D. Moudgil, "Immunomodulation of autoimmune arthritis by proc-inflammation Cytokines," Cytokine, vol. 98, pp. 87–96, 2017.
[9] T. M. Zhang, Clinical Chinese Pharmacy, China Traditional Chinese Medicine, Hong Kong, China.
[10] State Pharmacopoeia Commission, Chinese Pharmacopoeia 2020, p. 24, China Medical Science and Technology Press, Beijing, China, 2020.
[11] Y. S. Zhu, Y. Huang, L. Q. Cai et al., "The Chinese medicinal herbal formula 2YZ88 inhibits cell growth and promotes cell apoptosis in prostatic tumor cells," Oncology Reports, vol. 10, pp. 1633–1639, 2003.
[12] X. Zhang, L. Wang, and D. C. Chen, "Effect of rhubarb on gastrointestinal dysfunction in critically ill patients: a retrospective study based on propensity score matching," Chinese Medical Journal, vol. 131, no. 10, pp. 1142–1150, 2018.
[13] J. Kolodziejczyk-Czepas and J. Czepas, "Rhaponticin as an anti-inflammatory component of rhubarb: a minireview of the current state of the art and prospects for future research," Phytochemistry Reviews, vol. 8, no. 5, pp. 1375–1386, 2019.
[14] A. Panetz and J. Westendorf, "Anthranooid contents of rhubarb (Rheum undulatum L.) and other Rheum species and their toxicological relevance," European Food Research and Technology, vol. 210, pp. 97–101, 1999.
[15] S. P. Lin, P. M. Chu, S. Y. Tsai, M. H. Wu, and Y. C. Hou, "Pharmacokinetics and tissue distribution of resveratrol, emodin and their metabolites after intake of Polygonum cuspidatum in rats," Journal of Ethnopharmacology, vol. 144, pp. 671–676, 2012.
[16] Z. Teng, C. Yuan, F. Zhang et al., "Intestinal absorption and first - pass metabolism of polyphenol compounds in rat and their transport dynamics in Caco -2 cells," PLoS One, vol. 7, 2012.
[17] M. Bachmann and C. Schlatter, "Metabolism of [14C]emodin in the rat," Xenobiotica, vol. 11, no. 3, pp. 217–225, 1981.
[18] J. W. Liang, S. L. Hsu, P. P. Wu, and P. D. Chao, "Emodin pharmacokinetics in rabbits," Planta Medica, vol. 61, no. 5, pp. 406–408, 1995.
Evidence-Based Complementary and Alternative Medicine

[19] Q. X. Wang, C. Q. Wu, and Y. M. Liao, “Study on the toxicity and its mechanisms of rhubarb and its major constituents,” *Journal of Toxicology*, vol. 21, pp. 310–302, 2007.

[20] X. Liu, Y. Liu, Y. Qu, M. Cheng, and H. Xiao, “Metabolomic profiling of emodin-induced cytotoxicity in human liver cells and mechanistic study,” *Toxicological Research*, vol. 4, pp. 948–955, 2015.

[21] T. Luo, N. Li, Y. He et al., “Emodin inhibits human sperm functions by reducing sperm [Ca2+] i and tyrosine phosphorylation,” *Reproductive Toxicology*, vol. 51, pp. 14–21, 2015.

[22] H. Y. Liu, M. Gao, H. Xue et al., “A promising emodin-loaded poly (lactic-co-glycolic acid)-D-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles for liver cancer therapy,” *Pharmaceutical Research*, vol. 33, no. 1, pp. 217–236, 2016.

[23] L. Hu, R. Cui, H. Liu, and F. Wang, “Emodin and rhein decrease levels of hypoxia-inducible factor-1α in human pancreatic cancer cells and attenuate cancer cachexia in athymic mice carrying these cells,” *Oncotarget*, vol. 8, no. 50, pp. 88008–88020, 2017.

[24] C. Zu, M. Zhang, H. Xue et al., “Emodin induces apoptosis of human breast cancer cells by modulating the expression of apoptosis-related genes,” *Oncology Letters*, vol. 10, no. 5, p. 2919, 2015.

[25] L. Ma, Y. Yang, Z. Yin et al., “Emodin suppresses the nasopharyngeal carcinoma cells by targeting the chloride channels,” *Biomedicine & Pharmacotherapy*, vol. 90, pp. 615–625, 2017.

[26] Y.-J. Wang, Su-L. Huang, Y. Feng, M.-M. Ning, and L. Ying, “Emodin, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, regulates adipocyte function in vitro and exerts anti-diabetic effect in ob/ob mice,” *Acta Pharmacologica Sinica*, vol. 33, no. 9, pp. 1195–1203, 2012.

[27] B. Liu, S. J. Li, D. R. Yang, F. S. Dong, X. H. Huang, and T. Li, “Therapeutic effect of emodin in experimental periodontitis rats,” *Chinese Journal of Cellular and Molecular Immunology*, vol. 26, no. 4, p. 391, 2010.

[28] Q. Liu, F. Yu, N. Yu, M. Shi, and F. Wang, “Emodin worsens methioninecholine-deficient diet-induced non-alcoholic fatty liver disease in mice,” *Chinese Journal of Cellular and Molecular Immunology*, vol. 31, no. 5, p. 620, 2015.

[29] L. Li, X. Song, Z. Yin et al., “The antibacterial activity and action mechanism of emodin from Polygonum cuspidatum against Haemophilus parasuis in vitro,” *Microbiological Research*, vol. 18, no. 6, pp. 425–435, 2020.

[30] F. Duan, G. Xin, H. Niu, and W. Huang, “Chlorinated emodin as a natural antibacterial agent against drug-resistant bacteria through dual influence on bacterial cell membranes and DNA,” *Scientific Reports*, vol. 7, no. 1, Article ID 12721, 2017.

[31] R. Batool, E. Aziz, T. Mahmood, K. H. Benny, and T. K. Vincent, “Inhibitory activities of extracts of Rumex dentatus, Commelina benghalensis, Ajuga bracteosa, Ziziphus mauritiana as well as their compounds of gallic acid and emodin against dengue virus Asian,” *Asian Pacific Journal of Tropical Medicine*, vol. 11, no. 4, pp. 5–11, 2018.

[32] L. Zhao, W. Fei, C. Liang-Jun et al., “In vitro and in vivo studies of the inhibitory effects of emodin isolated from polygonum cuspidatum on coxsackievirus B,” *Molecules*, vol. 18, no. 10, pp. 11842–11858, 2013.

[33] S. W. Li, T. C. Yang, C. C. Lai et al., “Antiviral activity of aloe-emodin against influenza A virus via galectin-3 upregulation,” *European Journal of Pharmacology*, vol. 738, pp. 125–132, 2014.

[34] B. Tian and Y. Hua, “Concentration-dependence of prooxidant and antioxidant effects of aloe and aloe-emodin on DNA,” *Food Chemistry*, vol. 91, no. 3, pp. 413–418, 2005.

[35] L. Wu, B. Cai, S. Zheng, X. Liu, H. Cai, and H. Li, “Effect of emodin on endoplasmic reticulum stress in rats with severe acute pancreatitis,” *Inflammation*, vol. 36, no. 5, pp. 1020–1029, 2013.

[36] W. P. Song, Q. H. Guo, H. D. Jia, T.-T. Song, and L. Liu, “Effect of levosimendan on heart function and hs-CRP, IL-6, TNF-α levels in elderly patients with acute myocardial infarction complicated heart failure,” *Journal of Hainan Medical College*, vol. 22, no. 12, pp. 91–94, 2016.

[37] X. Song, X. Zhou, Y. Qin et al., “Emodin inhibits epithelial mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC chemokine ligand 5 secreted from adipocytes,” *International Journal of Molecular Medicine*, vol. 42, no. 1, pp. 579–588, 2018.

[38] S. L. Tian, Y. Yang, X. L. Liu, and Q. B. Xu, “Emodin attenuates blooymcin-induced pulmonary fibrosis via anti-inflammatory and anti-oxidative activities in rats,” *Medical Science Monitor*, vol. 24, pp. 1–10, 2018.

[39] M. Li, Q. Fu, Y. Li, S. Li, J. Xue, and S. Ma, “Emodin opposes chronic unpredictable mild stress induced depressive-like behavior in mice by upregulating the levels of hippocampal glucocorticoid receptor and brain-derived neurotrophic factor,” *Fitoterapia*, vol. 98, pp. 1–10, 2014.

[40] Q. U. Kai, S. H. E. N. Nai-ying, X. U. Xin-sen, and S. U. Haimbo, “Emodin induces human T cell apoptosis in vitro by ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction,” *Acta Pharmacologica Sinica*, vol. 34, pp. 1–12, 2013.

[41] H. Tong, K. Chen, H. Chen et al., “Emodin prolongs recipient survival time after orthotopic liver transplantation in rats by polarizing the Th1/Th2 paradigm to Tha,” *The Anatomical Record*, vol. 294, no. 3, pp. 445–452, 2011.

[42] S. J. Szabo, B. M. Sullivan, S. L. Peng, and L. H. Glimcher, “Molecular mechanisms regulating Th1 immune responses,” *Annual Review of Immunology*, vol. 21, pp. 713–758, 2003.

[43] A. Laurence, C. M. Tato, T. S. Davidson et al., “Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation,” *Immunity*, vol. 26, no. 3, pp. 371–381, 2007.

[44] J. Zhu, H. Yamane, and W. E. Paul, “Differentiation of effector CD4 T cell populations,” *Annual Review of Immunology*, vol. 28, pp. 445–489, 2010.

[45] B. Iain and G. Schett, “Cytokines in the pathogenesis of rheumatoid arthritis,” *Nature Reviews Immunology*, vol. 7, no. 6, pp. 429–442, 2007.

[46] R. P. H. Raijmakers, E. G. G. Sprenkeler, F. E. Aleva et al., “Toll-like receptor 2 induced cytotoxic T lymphocyte-associated protein 4 regulates Aspergillus-induced regulatory T-cells with proinflammatory characteristics,” *Scientific Reports*, vol. 7, Article ID 11500, 2017.

[47] C. A. Piccirillo and E. M. Shevach, “Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells,” *The Journal of Immunology*, vol. 167, pp. 1137–1140, 2001.

[48] E. Y. Woo, H. Yeh, C. S. Chu et al., “Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation,” *The Journal of Immunology*, vol. 168, pp. 4272–4276, 2002.

[49] C. G. Vinuesa, M. A. Linterman, D. Yu, and I. C. MacLennan, “Follicular helper T cells,” *Annual Review of Immunology*, vol. 34, pp. 335–368, 2016.
Evidence-Based Complementary and Alternative Medicine

[50] S. T. Crotty, “Follicular helper cell biology: a decade of discovery and diseases,” *Immunity*, vol. 50, no. 5, pp. 1132–1148, 2019.

[51] R. L. Sabado, S. Balan, and N. Bhardwaj, “Dendritic cell-based immunotherapy,” *Cell Research*, vol. 27, no. 1, pp. 74–95, 2017.

[52] C. Macri, E. S. Pang, T. Patton, and M. O’Keefe, “Dendritic cell subsets,” *Seminars in Cell & Developmental Biology*, vol. 84, pp. 11–21, 2018.

[53] J. Banchereau and R. M. Steinman, “DCs and the control of immunity,” *Nature*, vol. 392, pp. 245–252, 1998.

[54] S. Sakaguchi, N. Mikami, J.B. Wing, A. Tanaka, K. Ichiyama, and N. Ohkura, “Regulatory T cells and human disease,” *Annual Review of Immunology*, vol. 38, pp. 541–566, 2020.

[55] P. Baeten, L. Van Zeebroeck, M. Kleinewietfeld, N. Hellings, and B. Broux, “Improving the efficacy of regulatory T cell therapy,” *Clinical Reviews in Allergy and Immunology*, vol. 62, pp. 1–19, 2021.

[56] D. Shevryev and V. Tereshchenko, “Treg heterogeneity, function, and homeostasis,” *Frontiers in Immunology*, vol. 10, p. 3100, 2020.

[57] M. Panduro, C. Benoit, and D. Mathis, “Tissue Tregs,” *Annual Review of Immunology*, vol. 34, pp. 609–633, 2016.

[58] H. Sun, Z. Ye, L. Ning, F. Jin, J. Yan, and K. Wu, “Effect of emodin on T cell subsets in NOD mice with Nal-induced experimental autoimmune thyroiditis,” *Molecular Medicine Reports*, vol. 18, no. 5, pp. 4303–4312, 2018.

[59] Z. Qi, H. Xiang, L. Han et al., “Emodin alleviates intestinal barrier dysfunction by inhibiting apoptosis and regulating the immune response in severe acute pancreatitis,” *Pancreas*, vol. 50, no. 8, pp. 1202–1211, 2021.

[60] J. Xue, F. Chen, J. Wang et al., “Emodin protects against concanavalin A-induced hepatitis in mice through inhibiting activation of the p38 MAPK-NF-κB signaling pathway,” *Cellular Physiology and Biochemistry*, vol. 35, no. 4, pp. 1557–1570, 2015.

[61] J. Lee, H. J. Kim, T. T. Nguyen et al., “Emodin 8-O-glucoside primes macrophages more strongly than emodin aglycone via activation of phagocytic activity and TLR-2/MAPK/NF-κB signalling pathway,” *International Immunopharmacology*, vol. 88, Article ID 106936, 2020.

[62] W. Zhang, L. Hong, H. Bu et al., “Emodin inhibits the differentiation and maturation of dendritic cells and increases the production of regulatory T cells,” *International Journal of Molecular Medicine*, vol. 29, no. 2, pp. 159–164, 2012.

[63] Y.-Ho Hwang, Su-J. Kim, and S.-T. Yee, “Physcion-matured dendritic cells induce the differentiation of Th1 cells,” *International Journal of Molecular Sciences*, vol. 21, no. 5, p. 1753, 2020.

[64] F. Qiu, H. Liu, C.-L. Liang, G. D. Nie, and Z. Dai, “A new immunosuppressive molecule emodin induces both CD4+ FoxP3+ and CD8+ CD122+ regulatory T cells and suppresses murine allograft rejection,” *Frontiers in Immunology*, vol. 8, p. 1519, 2017.

[65] H. Källberg, B. Ding, L. Padyukov et al., “Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke,” *Annals of the Rheumatic Diseases*, vol. 70, pp. 508, 2011.

[66] U. Harre, D. Georgess, H. Bang et al., “Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin,” *Journal of Clinical Investigation*, vol. 122, pp. 1791–1802, 2012.

[67] A. Krishnamurthy, V. Joshua, A. Haj Hensvold et al., “Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss,” *Annals of the Rheumatic Diseases*, vol. 75, pp. 721–729, 2016.

[68] H. J. Ristow, “BSC-1 growth inhibitor/tyrptaminizing growth factor is a strong inhibitor of thymocyte proliferation,” *Proceedings of the National Academy of Sciences*, vol. 83, pp. 5531–5533, 1986.

[69] S. Das, “Genetic and expression changes in TNF-α as a risk factor for rheumatoid arthritis pathogenesis in northeast India,” *Journal of Genetics*, vol. 98, p. 3, 2019.

[70] S. Narimiya and H. Kanzaki, “Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression,” *BoneKey Reports*, vol. 11, Article ID 100228, 2019.

[71] T. Onogawa, T. Saito-Taki, H. Yamamoto, and T. Wada, “IL6 trans-signaling promotes functional recovery of hypofunctional phagocytes through STAT3 activation during peritonitis,” *Inflammation Research*, vol. 62, no. 8, pp. 797–810, 2013.

[72] T. R. Mosmann, H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman, “Two types of murine helper T-cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins,” *The Journal of Immunology*, vol. 136, pp. 2348–2357, 1986.

[73] C. Dong, T. Fu, J. Ji, Z. Li, and Z. Gu, “The role of interleukin-4 in rheumatic disease,” *Clin Exp Pharmacol Physiol*, vol. 45, no. 8, pp. 747–754, 2018.

[74] C. J. P. Clarke, A. Hales, A. Hunt, and B. M. Foxwell, “IL-10 mediated suppression of TNF-α production is independent of its ability to inhibit NF-кB activity,” *European Journal of Immunology*, vol. 28, pp. 1719–1726 49, 1998.

[75] D. Gerard, C. Bryns, A. Marchant et al., “Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia,” *Journal of Experimental Medicine*, vol. 177, pp. 547–550, 1993.

[76] A. Marchant, C. Bryns, P. Vandenabeele et al., “Interleukin-10 controls interferon-gand tumor necrosis factor production during experimental endotoxemia,” *European Journal of Immunology*, vol. 24, pp. 1167–1171, 1994.

[77] H. L. Dickensheets, S. L. Freeman, M. F. Smith, and R. P. Donnelly, “Interleukin-10 upregulates tumor necrosis factor receptor type II (p75) gene expression in endotoxin-stimulated human monocytes,” *Blood*, vol. 90, pp. 4162–4171, 1997.

[78] D. A. Joyce, D. P. Gibbons, P. Geen, J. H. Steer, M. Feldmann, and F. M. Brennan, “Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes,” *European Journal of Immunology*, vol. 24, pp. 2699–2705, 1994.

[79] R. Waale Mufley, C. G. Fidgor, R. Huijben et al., “Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes,” *The Journal of Immunology*, vol. 151, pp. 6370–6381, 1993.

[80] G. Zarawske and J. E. de Vries, “Interleukin 13, an interleukin-4-like cytokine that acts on monocytes and B cells, but not on T cells,” *Immunology Today*, vol. 15, pp. 19–26, 1994.

[81] A. N. McKenzie, X. Li, D. A. Largaespada et al., “Structural comparison and chromosomal localization of the human and mouse IL-13 genes,” *The Journal of Immunology*, vol. 150, pp. 5436–5444, 1993.
[82] T. Mijatovic, V. Kruys, D. Caput, P. Defrance, and G. Huez, “Interleukin-4 and -13 inhibit tumor necrosis factor-α mRNA translation in lipopolysaccharide-induced mouse macrophages,” Journal of Biological Chemistry, vol. 272, pp. 14394–14398, 1997.

[83] E. Di Santo, C. Meazza, M. Sironi et al., “IL-13 inhibits TNF production but potentiates that of IL-6 in vivo.” The Journal of Immunology, vol. 159, pp. 379–382, 1997.

[84] T. Muchamuel, S. Menon, P. Pisacane, M. C. Howard, and D. A. Cockayne, “IL-13 protects mice from lipopolysaccharide-induced lethal endotoxaemia: correlation with down-modulation of TNF-α, IFN-γ, and IL-12 production,” The Journal of Immunology, vol. 158, pp. 2898–2903, 1997.

[85] I. S. Junttila, “Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes,” Front Immunol, vol. 9, p. 888, 2018.

[86] W. L. Trepicchio, L. Wang, N. Bozza, and A. J. Dorner, “IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB,” The Journal of Immunology, vol. 159, no. 11, pp. 5661–5670, 1997.

[87] J. H. Kehrl, L. M. Wakefield, A. B. Roberts et al., “Production of transforming growth factor beta by mouse T lymphocytes and its potential role in the regulation of T cell growth,” Journal of Experimental Medicine, vol. 163, pp. 1037–1050, 1986.

[88] H. J. Ristow, “BSC-1 growth inhibitor/typetransforming growth factor is a strong inhibitor of thymocyte proliferation,” Proceedings of the National Academy of Sciences, vol. 83, pp. 5531–5533, 1986.

[89] V. Strand and A. F. Kavanaugh, “The role of interleukin-1 in bone resorption in rheumatoid arthritis,” Rheumatology, vol. 43, no. 1, 2004.

[90] S. Kar and R. Gupta, “Interleukin-9 facilitates osteoclastogenesis in rheumatoid arthritis,” International Journal of Molecular Sciences, vol. 22, no. 19, Article ID 10397, 2021.

[91] G. Hansen, T. R. Hercus, B. J. McClure et al., “The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation,” Cell, vol. 134, pp. 496–507, 2008.

[92] T. R. Hercus, U. Dhagat, W. L. Kan et al., “Signalling by the beta family of cytokines,” Cytokine & Growth Factor Reviews, vol. 24, pp. 189–201, 2013.

[93] C. Crotti, M. G. Raimondo, A. Becciolini, M. Biggioggero, and E. G. Favalli, “Spotlight on mavrilimumab for the treatment of rheumatoid arthritis,” Arthritis & Rheumatism, vol. 46, pp. 574–578, 2002.

[94] A. K. Ulfgren, L. Grondal, S. Lindblad et al., “Interindividual and intraarticular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment,” Annals of the Rheumatic Diseases, vol. 59, pp. 439–447, 2000.

[95] R. Wang, Q. Wan, Y. Zhang et al., “Emodin suppresses interleukin-1beta induced mesangial cells proliferation and extracellular matrix production via inhibiting P38 MAPK,” Life Sciences, vol. 80, no. 26, pp. 2481–2488, 2007.

[96] M. Chabaud and P. Miossec, “The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model,” Arthritis & Rheumatism, vol. 44, pp. 1293–1303, 2001.

[97] N. Jiang, W. Liao, and X. Kuang, “Effects of emodin on IL-23/IL-17 inflammatory axis, Th17 cells and viral replication in mice with viral myocarditis,” Nan Fang Yi Ke Da Xue Xue Bao, vol. 34, no. 3, pp. 373–378, 2014.

[98] G. Schett, “Cells of the synovium in eumonoid arthritis. Osteoclasts,” Arthritis Research & Therapy, vol. 9, p. 203, 2007.

[99] N. C. Walsh, S. Reinwald, C. A. Manning et al., “Osteoblast function is compro-mised at sites of focal bone erosion in inflammatory arthritis,” Bone and Mineral Research, vol. 24, pp. 1572–1585, 2009.

[100] J. Li and Y. Li, “Emodin attenuates titanium particle-induced osteolysis and RANKL-mediated osteoclastogenesis through the suppression of IKK Phosphorylation,” Molecular Immunology, vol. 96, pp. 8–18, 2018.

[101] A. Shiomi and T. Usui, “Pivotal roles of GM-CSF in autoimmunity and inflammation,” Mediators of Inflammation, vol. 2015, Article ID 568543, 13 pages, 2015.

[102] J. S. Wicks and A. W. Roberts, “Targeting GM-CSF in inflammatory diseases,” Nature Reviews Rheumatology, vol. 12, no. 1, pp. 37–48, 2016.

[103] N. Jiang, W. Liao, and X. Kuang, “Effects of emodin on IL-23/IL-17 inflammatory axis, Th17 cells and viral replication in mice with viral myocarditis,” Nan Fang Yi Ke Da Xue Xue Bao, vol. 34, no. 3, pp. 373–378, 2014.

[104] G. Schett, “Cells of the synovium in eumonoid arthritis. Osteoclasts,” Arthritis Research & Therapy, vol. 9, p. 203, 2007.
tyrosine phosphorylation,” *Blood*, vol. 92, no. 6, pp. 1989–2002, 1998.

[115] N. Sato, K. Sakamaki, N. Terada, K. Arai, and A. Miyajima, “Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling,” *EMBO Journal*, vol. 12, no. 11, pp. 4181–4189, 1993.

[116] S. E. Broughton, T. L. Nero, U. Dhagat et al., “The betacell receptor family—structural insights and their functional implications,” *Cytochrome*, vol. 74, no. 2, pp. 247–258, 2015.

[117] T. Leizer, J. Cebon, J. E. Layton, and J. A. Hamilton, “Cytochrome regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor,” *Blood*, vol. 76, no. 10, pp. 1989–1996, 1990.

[118] I. K. Campbell, U. Novak, J. Cebon, J. E. Layton, and J. A. Hamilton, “Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1,” *The Journal of Immunology*, vol. 147, no. 4, pp. 1238–1246, 1996.

[119] L. L. Bao, L. P. Qin, and Q. Y. Zhang, “Anthraquinone compounds from Morinda officinalis inhibit osteoclastic bone resorption in vitro,” *Chemico-Biological Interactions*, vol. 194, no. 2-3, pp. 97–105, 2011.

[120] J. K. Hwang, E. M. Noh, and Y. R. Lee, “Emodin suppresses inflammatory responses and joint destruction in collagen-induced arthritic mice,” *Rheumatology*, vol. 52, no. 9, pp. 1583–1591, 2013.

[121] S. M. Haikal, N. F. Abdeltawab, L. A. Rapid, T. I. Abd El-Sabour, and A. Y. S. Ali, “Emodin ameliorates experimental autoimmune myocarditis in rats,” *Tohoku Journal of Experimental Medicine*, vol. 227, no. 3, pp. 225–230, 2012.

[122] J. Stephen, J. Wang, D. Altomare, Y. Hui, and D. Fan, “Emodin bidirectionally modulates macrophage polarization and epigenetically regulates macrophage memory,” *Journal of Biological Chemistry*, vol. 291, no. 22, pp. 11491–11503, 2016.

[123] Y.-X. Liu, N.-Y. Shen, C. C. Liu, and Y. Lv, “Immunosuppressive effects of emodin: an in vivo and in vitro study,” *Transplantation Proceedings*, vol. 41, no. 5, pp. 1837–1839, 2009.

[124] S. Chen, B. Chen, Z. Wen, Z. Huang, and L. Ye, “IL-33/ST2-mediated inflammation in macrophages is directly abrogated by IL-10 during rheumatoid art,” *Oncotarget*, vol. 8, no. 20, pp. 32407–32418, 2017.

[125] M. Zhu, “Emodin ameliorates rheumatoid arthritis by promoting neutrophil apoptosis and inhibiting neutrophil extracellular trap formation,” *Molecular Immunology*, vol. 112, pp. 188–197, 2019.

[126] S. C. Gupta, “Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols,” *Archives of Biochemistry and Biophysics*, vol. 559, pp. 91–99, 2014.

[127] X. Chu, M. Wei, and X. Yang, “Effects of an anthraquinone derivative from *Rheum officinale* Baill, emodin, on airway responses in a murine model of asthma,” *Food and Chemical Toxicology*, vol. 50, no. 7, pp. 2368–2375, 2012.

[128] R. Bucala, C. Ritchlin, R. Winchester, and A. Cerami, “Constitutively produced of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts,” *Journal of Experimental Medicine*, vol. 173, no. 3, pp. 569–574, 1991.
Evidence-Based Complementary and Alternative Medicine

[147] M. Akdis, A. Aab, C. Altunbulakli et al., "Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: receptors, functions, and roles in diseases," The Journal of Allergy and Clinical Immunology, vol. 138, pp. 984–1010, 2016.

[148] E. V. Acosta-Rodriguez, G. Napolitani, A. Lanzavecchia, and F. Sallusto, "Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17 producing human T helper cells," Nature Immunology, vol. 8, pp. 942–949, 2007.

[149] D. Toy, D. Kugler, M. Wolfson et al., "Cutting edge: interleukin 17 signals through a heteromeric receptor complex," The Journal of Immunology, vol. 177, pp. 36–39, 2006.

[150] M. L. Toh, G. Gonzales, M. I. Koenders et al., "Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression," PLoS One, vol. 5, Article ID e13416, 2010.

[151] A. Hot, S. Zrioual, V. Lenief, and P. Miossec, "IL-17 and tumour necrosis factor alpha combination induces a HIF-1alpha-dependent invasive phenotype in synoviocytes," Annals of the Rheumatic Diseases, vol. 71, pp. 1393–1401, 2012.

[152] C. Zenobia and H. George, "Basic biology and role of interleukin-17 in immunity and inflammation," Periodontology, vol. 69, no. 1, pp. 142–159, 2015.

[153] J. Chen, L. Guan, L. Tang et al., "T helper 9 cells: a new player in immune-related diseases," DNA and Cell Biology, vol. 38, no. 10, pp. 1040–1047, 2019.

[154] D. Metcalf, "The colony-stimulating factors and cancer," Nature Reviews Cancer, vol. 10, pp. 425–434, 2010.

[155] A. S. Cowburn, C. Summers, B. J. Dunmore et al., "Granulocyte/macrophage colony-stimulating factor causes a paradoxical increase in the BH3-only pro-apoptotic protein Bim in human neutrophils," American Journal of Respiratory Cell and Molecular Biology, vol. 44, pp. 879–887, 2011.

[156] A. L. Cornish, I. K. Campbell, B. S. McKenzie, S. Chatfield, and I. P. Wicks, "G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis," Nature Reviews Rheumatology, vol. 5, no. 10, pp. 554–559, 2009.

[157] M. Dougan, G. Dranoff, and S. K. Dougan, "GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation," Immunity, vol. 50, no. 4, pp. 796–811, 2019.

[158] M. A. Brown and J. Hural, "Functions of IL-4 and control of its expression," Critical Reviews in Immunology, vol. 17, pp. 1–32, 1997.

[159] P. Wang, P. Wu, M. L. Siegel, R. W. Egan, and M. M. Billah, "Interleukin (IL)-10 inhibits nuclear factorkB (NF-kB) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms," Journal of Biological Chemistry, vol. 270, pp. 9558–9563, 1995.

[160] A. A. Te Velde, R. J. F. Huijbens, J. E. De Vries, J. E. De Vries, and C. G. Figdor, "Interleukin-4 (IL-4) inhibits secretion of IL-1b, tumor necrosis factora, and human IL-6 by human monocytes," Blood, vol. 76, pp. 1392–1397, 1990.

[161] W. E. Paul, "Interleukin-4: a prototypic immunoregulatory lymphokine," Blood, vol. 77, pp. 1859–1870, 1991.

[162] M. W. Babjatsky, G. Rossiter, and D. K. Podolsky, "Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease," Gastroenterology, vol. 110, pp. 975–984, 1996.

[163] J. J. Letterio and A. B. Roberts, "Regulation of immune responses by TGF-beta," Annual Review of Immunology, vol. 16, pp. 137–161, 1998.

[164] J. J. Letterio and A. B. Roberts, "TGF-b: a critical modulator of immune cell function," Clinical Immunology and Immunopathology, vol. 84, pp. 244–250, 1997.

[165] A. B. Roberts and M. B. Sporn, "Differential expression of the TGF-hisoforms in embryogenesis suggests specific roles in developing and adult tissues," Molecular Reproduction and Development, vol. 32, pp. 91–98, 1992.

[166] M. M. Shull, I. Ormsby, A. B. Kier et al., "Targeted disruption of the mouse transforming growth factor-b1 gene results in multifocal inflammatory disease," Nature, vol. 359, pp. 693–699, 1992.

[167] W. Chen, W. Jin, N. Hardegen et al., "Conversion of peripheral CD4CD25 naïve T cells to CD4CD25 regulatory T cells by TGF-binding of transcription factorFoxp3," Journal of Experimental Medicine, vol. 198, pp. 1875–1886, 2003.

[168] J.-H. Lee, H. Nam, S. Um, J. Lee, G. Lee, and B. M. Seo, "Upregulation of GM-CSF by TGF-b1 in epithelial mesenchymal transition of human HERS/ERM cells," In Vitro Cellular & Developmental Biology Animal, vol. 50, no. 5, pp. 399–405, 2014.

[169] G. Carvajal Alegria, D. Cornece, A. Saraux et al., "Abatacept promotes regulatory B cell functions, enhancing their ability to reduce the Th1 response in rheumatoid arthritis patients through the production of IL-10 and TGF-beta," The Journal of Immunology, vol. 207, no. 2, pp. 470–482, 2021.

[170] G. E. Fragoulis, J. Brock, N. Basu, I. B. McInnes, and S. Siebert, "The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions," The Journal of Allergy and Clinical Immunology, vol. 148, no. 4, pp. 941–952, 2021.

[171] D. Metcalf, "Hematopoietic cytokines," Blood, vol. 111, pp. 485–491, 2008.